Relay Therapeutics Inc 2020 SR
The report outlines Relay Therapeutics' ESG performance for the 2020 fiscal year, focusing on its Dynamo platform for drug discovery in oncology and genetic diseases. Key highlights include the initiation of two Phase 1 clinical trials and a workforce of 148 employees. The company achieved a 98% employee recommendation rate and conducted a gender pay gap analysis showing no discrepancies. Environmental efforts featured LEED Gold certification for its headquarters and a 39% reduction in water usage through efficient fixtures. Governance is overseen by the Board's Nominating and Corporate Governance Committee, with 38% gender and racial diversity on the Board.
Company: Relay Therapeutics Inc
Sector: Professional & technical services
Country: United States
Year: 2020
Type: SR
Pages: 21
Back to company
Relay Therapeutics Inc
ESG Summary
The report outlines Relay Therapeutics' ESG performance for the 2020 fiscal year, focusing on its Dynamo platform for drug discovery in oncology and genetic diseases. Key highlights include the initiation of two Phase 1 clinical trials and a workforce of 148 employees. The company achieved a 98% employee recommendation rate and conducted a gender pay gap analysis showing no discrepancies. Environmental efforts featured LEED Gold certification for its headquarters and a 39% reduction in water usage through efficient fixtures. Governance is overseen by the Board's Nominating and Corporate Governance Committee, with 38% gender and racial diversity on the Board.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women on Board
Women in Management
Workplace Fatalities
Employees